[
1. Kim DY, Jung KH, Kim TH, Kim DW, Chang HJ, Jeong JY, et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67: 378-84.10.1016/j.ijrobp.2006.08.06317097835
]Search in Google Scholar
[
2. Chan AK, Wong AO, Jenken DA. Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer-is it equivalent to 5-FU infusion plus leucovorin and radiotherapy? Int J Radiat Oncol Biol Phys 2010; 76: 1413-9.
]Search in Google Scholar
[
3. Velenik V, Ocvirk J, Oblak I, Anderluh F. Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial. Radiol Oncol 2012; 46: 252-7.10.2478/v10019-012-0030-2347295123077464
]Search in Google Scholar
[
4. Pesta M, Topolcan O, Holubec L Jr, Rupert K, Cerna M, Holubec LS, et al. Clinicopathological assesment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 2007; 27: 1863-7.
]Search in Google Scholar
[
5. Li M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metaloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth and angiogenesis. Exp Biol Med 2006; 231: 20-7.10.1177/15353702062310010316380641
]Search in Google Scholar
[
6. Giaginis C, Nikiteas N, Margeli A, Tzanakis N, Rallis G, Kouraklis G, et al. Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: association with clinicopathological variables and patients survival. Int J Biol Markers 2009; 24: 245-52.10.1177/172460080902400405
]Search in Google Scholar
[
7. Alo-Aho R, Kahari VM: Colagenases in cancer. Biochemie 2005; 87: 273-86.
]Search in Google Scholar
[
8. Sørensen NM, Sørensen IV, Wűrtz SØ, Schrohl AS, Dowell B, Davis G, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scan J Gastroenterol 2008; 43: 774-86.10.1080/0036552070187816318584515
]Search in Google Scholar
[
9. Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, et al. Assesment of the biological variation of plasma tissue inhibitor of metalloproteinase-1. Int J of Biological Markers 2008; 23: 42-7.10.1177/172460080802300107
]Search in Google Scholar
[
10. Wass ET, Hendriks T, Lomme RM, Woblles T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005; 48: 700-10.10.1007/s10350-004-0854-y15906450
]Search in Google Scholar
[
11. Kahlert C, Bandapalli OR, Schirmacher P, Weitz J, Brand K. Invasion frontspecific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer. Anticancer Res 2008; 28: 1459-66.
]Search in Google Scholar
[
12. Oblak I, Anderluh F, Velenik V, Mozina B, Ocvirk J, Ciric E, et al. Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II-III. Radiol Oncol 2011; 45: 209-12.10.2478/v10019-011-0027-2342373822933958
]Search in Google Scholar
[
13. Sørensen NM, Byström P, Christensen IJ, Berglund A, Nielsen HJ, Brüner N, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients reciving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 2007; 13: 4117-22.10.1158/1078-0432.CCR-07-018617634538
]Search in Google Scholar
[
14. Unsal D, Under A, Akyurek N, Erpolat P, Dursun A, Pak Y. Matrix metalloproteinase-9 expression correlates with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy. Int JRadiol Oncol Biol Phys 2007; 67: 196-203.10.1016/j.ijrobp.2006.08.01017071013
]Search in Google Scholar
[
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.10.1080/01621459.1958.10501452
]Search in Google Scholar
[
16. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.10.1038/bjc.1977.12025310831755
]Search in Google Scholar
[
17. Cox DR. Regression models and life-tables. J R Stat Soc Bull 1972; 34: 187-220.10.1111/j.2517-6161.1972.tb00899.x
]Search in Google Scholar
[
18. Holten-Andersen MN, Nielsen HJ, Sørensen S, Jensen V, Brűner N, Christensen IJ. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 2006; 42: 1886-96.10.1016/j.ejca.2006.01.05816809030
]Search in Google Scholar
[
19. Yakawa N, Yoshikawa T, Akaike M, Sugimasa Y, Rino Y, Masuda M, et al. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on longterm survival in patients with colorectal cancer. Oncology 2007; 72: 205-8.10.1159/00011282718160809
]Search in Google Scholar
[
20. Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol 2010; 5: 88-96.10.1186/1748-717X-5-88295559420920276
]Search in Google Scholar
[
21. Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. StrachlentherOncol 2008; 184: 450-6.10.1007/s00066-008-1751-419016023
]Search in Google Scholar
[
22. Holten-Anderson MN, Christensen IJ, Nielsen HJ, Lilja H, Murphy G, Jensen V, et al. Measurement of the non-complex free fraction of tissue inhibitor of metalloproteinases I in plasma by immunoassay. Clin Chem 2002; 48: 1305-13.10.1093/clinchem/48.8.1305
]Search in Google Scholar
[
23. Holten-Anderson M, Christensen IJ, Nilberg M, Bendahl PO, Nielsen HJ, Brűnner N, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study. Eur J of Cancer 2004; 40: 64-72.10.1016/j.ejca.2003.09.01914687791
]Search in Google Scholar
[
24. Ishida H, Murata N, Hayashi Y, Tada M, Hashimoto D. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP- 1) in colorectal cancer patients. Surg Today 2003; 33: 885-92.10.1007/s00595-003-2628-x14669077
]Search in Google Scholar
[
25. Tayebjee MH, Lip GYH, Blann AD, MacFadyen RJ. Effects of age, gender, ethnicity, diurnal variations and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and-9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 2005; 115: 205-10.10.1016/j.thromres.2004.08.023
]Search in Google Scholar
[
26. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003; 39: 718-27.10.1016/S0959-8049(02)00811-0
]Search in Google Scholar
[
27. Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM, et al. Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol 2010; 8: 27.
]Search in Google Scholar
[
28. Laohavinij S, Maneechavakaiorn J, Techatanol P. Prognostic factors for survival in colorectal cancer patients. J Med Assoc Thai 2010; 93: 1156-66.
]Search in Google Scholar
